Is the 'sodium index' a useful way of expressing clinical plasma renin, angiotensin and aldosterone values?

Angiotensin II in primary hypertension, relationship to plasma renin activity, aldosterone and urinary electrolytes

Plasma concentrations of angiotensin II (AII) were studied in 36 patients with primary (essential) hypertension and 15 normotensive control subjects during basal (1 h supine rest), upright and frusemide-stimulated (80 mg orally) conditions. Plasma renin activity (PRA) and plasma aldosterone (PA) were determined on the same occasions. AII was then correlated statistically to PRA, PA and 24-hour urinary excretions of aldosterone (Aldo-U), sodium and potassium and to the blood pressure (BP) levels. The AII values in the hypertensive patients were not statistically significantly different from those in the normotensive subjects. A close relationship was found between the AII values and the corresponding PRA values in the hypertensive patients (r=0.65--0.76, p less than 0.001 for all). Correlations between AII and PA, and AII and Aldo-U were not consistently significant. No correlation was found between AII and BP or between AII and 24-hour urinary electrolytes. The findings point to an intact function between PRA and AII but a disturbed AII-aldosterone interrelation in primary hypertension.

Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function

The converting enzyme inhibitor, ramipril, 20 mg once daily, was given to 3 hypertensive patients with unilateral renovascular disease. At 1 month, 24 hours after the last dose of ramipril, blood pressure, plasma angiotensin II and converting enzyme activity remained low, and active renin and angiotensin I high. There was no tendency for converting enzyme inhibition to be overcome during 1 month of ramipril therapy. Ramipril caused slight increases in serum potassium and urea, no change in serum creatinine and no consistent changes in the renal vein renin ratio. Ramipril caused little change in renal plasma flow on the stenotic side, but filtration fraction was reduced in 2 patients. There was no serious deterioration in total or individual glomerular filtration rate during ramipril therapy. The drug was well tolerated and there were no serious side effects. Ramipril, given once daily, is likely to be effective in controlling hypertension with renal artery stenosis.

Endogenous angiotensin-aldosterone-pressure relationships during sodium restriction

The effects of moderate restriction of dietary sodium and potassium supplementation on plasma levels of renin, angiotensin II, aldosterone, and cortisol and on arterial pressure were studied in 12 patients with mild essential hypertension. To define hormone-blood pressure relationships, venous hormone levels were measured hourly and intra-arterial pressure continuously for 24 hours after 4 to 6 weeks of sodium restriction, 4 to 6 weeks of potassium supplementation, and a similar period of control diet. Our results show that compared with the control diet, moderate sodium restriction was associated with increased levels of aldosterone but no overall change in renin, angiotensin II, or cortisol levels. Further, slopes of regression lines relating log renin and log angiotensin II to aldosterone were increased, as were log cortisol/aldosterone regression lines. On the contrary, regression lines of log renin and log angiotensin II versus arterial pressure were unaltered by sodium restriction. Hormone and blood pressure relationships were not changed by the potassium supplemented diet. Although confirmatory data are needed, our findings suggest that moderate sodium restriction enhances aldosterone responsiveness to endogenous angiotensin II and adrenocorticotropic hormone without diminishing the pressor activity of endogenous angiotensin II. These results may explain in part the disappointingly small hypotensive effect of modest sodium restriction in mild essential hypertension.

Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition

The converting enzyme inhibitor enalapril, in single daily doses of 10 to 40 mg, was given to 20 hypertensive patients with renal artery stenosis. The decrease in blood pressure six hours after the first dose of enalapril was significantly related to the pretreatment plasma concentrations of active renin and angiotensin II, and to the concurrent decrease in angiotensin II. Blood pressure decreased further with continued treatment; the long-term decrease was not significantly related to pretreatment plasma renin or angiotensin II levels. At three months, 24 hours after the last dose of enalapril, blood pressure, plasma angiotensin II, and converting enzyme activity remained low, and active renin and angiotensin I high; six hours after dosing, angiotensin II had, however, decreased further. The increase in active renin during long-term treatment was proportionately greater than the increase in angiotensin I; this probably reflects the diminution in renin substrate that occurs with converting enzyme inhibition. Long-term enalapril treatment increased renin secretion by more than 10-fold, and renal venous and peripheral plasma renin concentration by more than 20-fold; however, the mean renal venous renin ratio was not changed. Enalapril caused a reduction in effective renal plasma flow via the affected kidney but a marked and consistent increase on the contralateral side, where renal vascular resistance decreased. The overall increase in effective renal plasma flow was significantly related to the decrease in angiotensin II. Overall glomerular filtration rate was lowered, and serum creatinine and urea increased. Enalapril alone caused a long-term reduction in exchangeable sodium, with slight but distinct increases in serum potassium. In five patients with bilateral renal artery lesions, enalapril given alone for three months did not cause renal function to deteriorate. Enalapril was well tolerated and provided effective long-term control of hypertension; only two of the 20 patients studied required concomitant diuretic treatment.

Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension

To determine whether moderate restriction of dietary sodium content or supplementation of potassium intake reduces blood-pressure in patients with mild essential hypertension, twelve patients were put on three different diets--a control diet (180 mmol sodium/day), a sodium restricted diet (80 mmol/day). Each diet was taken for at least 4 weeks and the sequence of the regimens was randomised. At the completion of each regimen intra-arterial pressure was recorded continuously, and vasoactive hormones were measured hourly, for 24 h, under standardised conditions, in hospital. Compared with the control diet, sodium restriction was associated with lower blood-pressure readings in seven patients, higher levels in five, and an overall reduction in mean pressures of only 4.0/3.0 mm Hg (not significant). Individual differences in blood-pressure between these two diets correlated closely with concomitant differences in plasma renin activity (r = 0.75). Potassium supplementation also resulted in variable changes in arterial pressure, and the mean difference in pressure recordings (0.1/0.8 mm Hg) was insignificant. The results show that moderate restriction of sodium intake or supplementation of dietary potassium has variable effects on arterial pressure in individuals with mild essential hypertension, and that overall the blood-pressure changes induced are very small. Responsiveness of the renin-angiotensin system may limit the fall in blood-pressure induced by sodium restriction.

Supine and standing plasma catecholamines in essential hypertensive patients with different renin levels

In this study we measured plasma renin activity (PRA), plasma norepinephrine (NE) and epinephrine (E), heart rate (HR) and blood pressure (BP) in 89 supine (sup) essential hypertensive patients (pts), WHO I-II, after 3-5 days of fixed normal sodium and potassium intake; the same measurements were repeated after 30' of active standing (stand) in 44/89 pts. In the whole population NE was directly related to PRA, both in sup and in stand position (p less than 0.01). NE was above the upper limits of normotensive controls in 2/34 (6%) pts with low PRA, in 6/40 (17%) pts with normal PRA and in 6/15 (40%) pts with high PRA. In respect to normal PRA pts, HR was significantly lower in low PRA pts and higher in high PRA pts, both in sup and in stand position (p less than 0.05). Sup and stand NE and E were similar in low and normal PRA pts, while they were significantly higher in high PRA pts (p less than 0.05). These results suggest an increased adrenergic tone at least in some high PRA pts, and blunted responsiveness of renal and cardiac beta adrenergic receptors to adrenergic stimuli in low PRA pts.

Enalapril in the treatment of hypertension with renal artery stenosis

The converting enzyme inhibitor enalapril, in single daily doses of 10-40 mg, was given to 20 hypertensive patients with renal artery stenosis. The blood pressure fall six hours after the first dose of enalapril was significantly related to the pretreatment plasma concentrations of active renin and angiotensin II and to the concurrent fall in angiotensin II. Blood pressure fell further with continued treatment; the long term fall was not significantly related to pretreatment plasma renin or angiotensin II concentrations. At three months, 24 hours after the last dose of enalapril, blood pressure, plasma angiotensin II, and converting enzyme activity remained low and active renin and angiotensin I high; six hours after dosing, angiotensin II had, however, fallen further. The rise in active renin during long term treatment was proportionally greater than the rise in angiotensin I; this probably reflects the fall in renin substrate that occurs with converting enzyme inhibition. Enalapril alone caused reduction in exchangeable sodium, with distinct increases in serum potassium, creatinine, and urea. Enalapril was well tolerated and controlled hypertension effectively long term; only two of the 20 patients required concomitant diuretic treatment.

Measurement of urine electrolytes: clinical significance and methods

There are specific clinical settings in which each of the urine electrolytes may be diagnostically useful. The urine sodium alone is not efficient in differentiating prerenal azotemia from acute tubular necrosis, but if urine sodium is coupled with some measure of the renal concentrating ability, e.g., the urine:plasma creatinine ratio. discrimination between these two conditions is much improved. Usefulness of the urine sodium in other settings (evaluation of hyponatremia, prediction of acute rejection in renal transplant recipients, index of salt balance) is controversial. Urine potassium may be useful in the evaluation of hypokalemia of obscure etiology and, occasionally, in the form of the urinary Na/K ratio, as a guide to diuretic therapy. Urine chloride is assuming importance in the differential diagnosis of metabolic alkalosis, particularly when Bartter's syndrome is a consideration.

Renin levels and cardiovascular morbidity: a prospective study of the effect of beta-adrenergic blocking drugs

A 3-year prospective study was undertaken to evaluate the relationship between plasma renin activity levels and the incidence of cardiovascular complications in white patients with uncomplicated essential hypertension treated with various beta-adrenergic blocking agents (oxprenolol, pindolol, propranolol, sotalol and timolol). During the follow-up study, 4 (5.9%) of 68 treated patients and 10 (41.7%) of 24 non-treated patients (p less than 0.001) developed cardiovascular complications. The cardiovascular events occurred more frequently in patients with low renin activity levels and in patients with severe hypertension (diastolic blood pressure above 120 mmHg). An increase in plasma renin activity levels was observed following cardiovascular complications in both groups of patients. No cases of myocardial infarction occurred among the treated patients, while 5 cases (3 fatal) of proven myocardial infarction occurred among the non-treated patients. The results of this study suggest that low plasma renin activity levels have no "protective effect" on the incidence of cardiovascular complications in patients with essential hypertension. The fact that no cases of myocardial infarction were observed among patients treated with various beta-adrenergic blocking drugs suggests that these drugs may have a "cardioprotective" effect on ischaemic heart disease in patients with essential hypertension. This hypothesis should be confirmed by further trials.